Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

342
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
342
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

304
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

575
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
575
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

405
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

718
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
718
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

615
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
615

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).

Human vaccines & immunotherapeutics·2026
Same author

Anti-Integrin αvβ6 Autoantibodies as Diagnostic and Monitoring Biomarkers for Pediatric-Onset Primary Sclerosing Cholangitis.

Hepatology research : the official journal of the Japan Society of Hepatology·2026
Same author

Guidelines for the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis 2025 Supplement.

The Journal of dermatology·2026
Same author

Comparison of three pediatric studies investigating acute hepatitis of unknown etiology.

World journal of virology·2026
Same author

Pediatric Acute Liver Failure in Japan: Nationwide Survey Based on a National Classification Framework.

Hepatology research : the official journal of the Japan Society of Hepatology·2025
Same author

Functional analysis of novel and recurrent RINT1 variants in patients with infantile liver dysfunction.

Journal of human genetics·2025

Related Experiment Video

Updated: Mar 6, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Pediatric hepatitis B treatment.

Haruki Komatsu1, Ayano Inui2, Tomoo Fujisawa2

  • 1Department of Pediatrics, Toho University Sakura Medical Center, Chiba, Japan.

Annals of Translational Medicine
|March 3, 2017
PubMed
Summary

Treating chronic hepatitis B in children is challenging. Antiviral therapy aims for HBeAg seroconversion, but its long-term impact and cost-effectiveness require further study in pediatric HBV infection.

Keywords:
Seroconversionchildrenhepatocellular carcinoma (HCC)interferonnucleos(t)ide analogue (NAs)

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.9K

Related Experiment Videos

Last Updated: Mar 6, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

4.9K

Area of Science:

  • Hepatology
  • Pediatric Infectious Diseases
  • Virology

Background:

  • Hepatitis B vaccination reduces carriers, but chronic hepatitis B (CHB) in children remains a challenge.
  • HBeAg seroconversion is a primary treatment goal, though spontaneous seroconversion is common in children.
  • Identifying children needing antiviral treatment for CHB is crucial for effective management.

Purpose of the Study:

  • To review current guidelines and expert opinions on identifying and treating children with chronic hepatitis B.
  • To discuss first-line antiviral treatments, including interferon-alpha and nucleos(t)ide analogues (NAs), based on disease severity.
  • To highlight the need for clarity on the long-term clinical impact and cost-effectiveness of antiviral therapy in pediatric HBV infection.

Main Methods:

  • Review of existing guidelines and expert recommendations for pediatric chronic hepatitis B management.
  • Analysis of current antiviral treatment options, including interferon-alpha and various nucleos(t)ide analogues (NAs).
  • Consideration of factors like disease progression, drug resistance, and age-appropriateness of treatments.

Main Results:

  • Interferon-alpha is a first-line treatment for CHB without decompensated cirrhosis; NAs are used if cirrhosis is present.
  • NAs like entecavir and tenofovir are preferred for their high genetic barriers against drug resistance.
  • Optimal NA treatment duration and long-term adverse events in children remain unclear.

Conclusions:

  • Antiviral treatment strategies for pediatric CHB vary based on cirrhosis presence and drug resistance profiles.
  • The financial burden and lack of definitive evidence on preventing liver disease progression necessitate further research.
  • Clarifying the clinical impact of antiviral therapy is imperative for optimizing treatment decisions in children with HBV infection.